Incannex Healthcare (IXHL) vs Rockwell Medical (RMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rockwell Medical (RMTI) has outperformed Incannex Healthcare (IXHL) over the past year, losing 33.7% versus a loss of 75.3%. Incannex Healthcare is the larger company by market cap ($38.9 million vs $31.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IXHL | RMTI |
|---|---|---|
| Share price | $3.10 | $7.89 |
| Market cap | $38.89M | $31.80M |
| 1-day change | -3.13% | -1.62% |
| YTD return | -70.20% | -3.37% |
| 1-year return | -75.31% | -33.72% |
| 5-year return | — | -87.85% |
| Forward P/E | — | 112.71 |
| EPS (TTM) | $-1.66 | $-1.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.91 | $12.90 |
| 52-week low | $2.49 | $4.89 |
| Distance from 52-week high | -79.21% | -38.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +502.58% | +153.49% |
| Average volume | 94.75K | 26.44K |
| Shares outstanding | 12.54M | 4.03M |
| Employees | 12 | 157 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RMTI has outperformed IXHL by 41.6 percentage points over the past year.
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees
IXHL vs RMTI FAQ
Which is bigger, Incannex Healthcare or Rockwell Medical?
Incannex Healthcare (IXHL) is larger, with a market capitalization of $38.89M compared with $31.80M for Rockwell Medical (RMTI).
Which stock has performed better over the past year, IXHL or RMTI?
RMTI returned -33.72% over the past 12 months, compared with -75.31% for IXHL (price return, excluding dividends). Past performance does not predict future results.
Are Incannex Healthcare and Rockwell Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.